NCT04863703

Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 11 (estimated)
• Sponsor: Hannover Medical School · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Portal hypertension (PH) is one of the key drivers of clinical deteoration in patients with liver cirrhosis. It has been demonstrated that antiviral therapy in patients with chronic hepatitis C infection leads to a decrease of PH and is associated with an improved outcome. Recently, Bulevirtide was approved for the treatment of patients coinfected with hepatitis B (HBV) and chronic hepatitis delta (HDV) infection, which helps to achieve viral supression in these patients. This study investigates the potential effects of viral supression on PH in patients with chronic HBV/HDV infection and liver cirrhosis.

Conditions

• Hepatitis D
• Hepatitis B
• Portal Hypertension
• Liver Cirrhosis

Interventions

Type	Name	Description
DRUG	Bulevirtide	Patients with liver cirrhosis and HBV/HDV coinfection receive Bulevirtide as an antiviral therapy irrespective of the study, this study is observational.

Timeline

• Start date: 2021-05-07
• Primary completion: 2024-11-30
• Completion: 2026-12-31
• First posted: 2021-04-28
• Last updated: 2025-09-15

Locations

1 site across 1 country: Germany